How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis
(2022)
Journal Article
Faria, R., Saramago, P., Cox, E., Weng, S., Iyen, B., Akyea, R. K., …Woods, B. (2023). How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis. Atherosclerosis, 367, 40-47. https://doi.org/10.1016/j.atherosclerosis.2022.12.001
Background and aims
This study aimed to ascertain how the long-term benefits and costs of diagnosis and treatment of familial hypercholesterolaemia (FH) vary by prognostic factors and ‘cholesterol burden’, which is the effect of long-term exposure t...
Read More about How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.